1-12 of 12
Michael Andreeff
Close
Sort by
Journal Articles

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models

Clinical Trials & Observations
Mary Figueroa, Huaxian Ma, Mansour Alfayez, Daniel Enrique Morales-Mantilla, Fei Wang, Yue Lu, Marcos R. Estecio, Katherine Y. King, Eugenie Kleinerman, Seyed Javad Moghaddam, Naval Daver, Michael Andreeff, Marina Konopleva, Courtney DiNardo, Joya Chandra
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6624–6629.
https://doi.org/10.1182/bloodadvances.2023010111
Published: 2023
Includes: Supplemental data
Journal Articles

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Alexandre Bazinet, Tapan Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang, Sanam Loghavi, Jeffrey Jorgensen, Keyur Patel, Courtney DiNardo, Naval Daver, Yesid Alvarado, Fadi G. Haddad, Sherry Pierce, Graciela Nogueras Gonzalez, Abhishek Maiti, Koji Sasaki, Musa Yilmaz, Philip Thompson, William Wierda, Guillermo Garcia-Manero, Michael Andreeff, Elias Jabbour, Marina Konopleva, Xuelin Huang, Hagop Kantarjian, Farhad Ravandi
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3284–3296.
https://doi.org/10.1182/bloodadvances.2022009391
Published: 2023
Includes: Supplemental data
Journal Articles

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Ghayas C. Issa, Aram Bidikian, Sangeetha Venugopal, Marina Konopleva, Courtney D. DiNardo, Tapan M. Kadia, Gautam Borthakur, Elias Jabbour, Naveen Pemmaraju, Musa Yilmaz, Nicholas J. Short, Abhishek Maiti, Koji Sasaki, Lucia Masarova, Sherry Pierce, Koichi Takahashi, Guilin Tang, Sanam Loghavi, Keyur Patel, Michael Andreeff, Kapil Bhalla, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Naval Daver
Journal: Blood Advances
Blood Adv (2023) 7 (6): 933–942.
https://doi.org/10.1182/bloodadvances.2022008316
Published: 2023
Includes: Supplemental data
Journal Articles

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy

Hussein A. Abbas, Zoe Alaniz, Sean Mackay, Matthew Cyr, Jing Zhou, Ghayas C. Issa, Mansour Alfayez, Jairo Matthews, Steven M. Kornblau, Elias Jabbour, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Naval Daver
Journal: Blood Advances
Blood Adv (2021) 5 (22): 4569–4574.
https://doi.org/10.1182/bloodadvances.2021004583
Published: 2021
Includes: Supplemental data
Journal Articles

Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition

Kaori Saito, Qi Zhang, Haeun Yang, Kotoko Yamatani, Tomohiko Ai, Vivian Ruvolo, Natalia Baran, Tianyu Cai, Helen Ma, Rodrigo Jacamo, Vinitha Kuruvilla, Junichi Imoto, Sonoko Kinjo, Kazuho Ikeo, Kaori Moriya, Koya Suzuki, Takashi Miida, Yong-Mi Kim, Christopher P. Vellano, Michael Andreeff, Joseph R. Marszalek, Yoko Tabe, Marina Konopleva
Journal: Blood Advances
Blood Adv (2021) 5 (20): 4233–4255.
https://doi.org/10.1182/bloodadvances.2020003661
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Clinical Trials & Observations
Abhishek Maiti, Courtney D. DiNardo, Sa A. Wang, Jeffrey Jorgensen, Tapan M. Kadia, Naval G. Daver, Nicholas J. Short, Musa Yilmaz, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Alessandra Ferrajoli, Elias J. Jabbour, Nitin Jain, Guillermo Garcia-Manero, Maro Ohanian, Koichi Takahashi, Guillermo Montalban-Bravo, Lucia Masarova, Jan A. Burger, Philip A. Thompson, Srdan Verstovsek, Koji Sasaki, Michael Andreeff, Caitlin R. Rausch, Kathryn S. Montalbano, Sherry Pierce, Wei Qiao, Jing Ning, Hagop M. Kantarjian, Marina Y. Konopleva, Farhad Ravandi
Journal: Blood Advances
Blood Adv (2021) 5 (7): 1876–1883.
https://doi.org/10.1182/bloodadvances.2020003717
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Clinical Trials & Observations
Nicholas J. Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, Jing Ning, Miguel J. Franquiz, Rashmi Kanagal-Shamanna, Keyur P. Patel, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Koichi Takahashi, Marina Konopleva, Naval Daver, Ghayas C. Issa, Michael Andreeff, Hagop Kantarjian, Tapan M. Kadia
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5681–5689.
https://doi.org/10.1182/bloodadvances.2020003120
Published: 2020
Includes: Supplemental data
Journal Articles

Clinical value of event-free survival in acute myeloid leukemia

Clinical Trials & Observations
Abhishek Maiti, Hagop M. Kantarjian, Vinita Popat, Gautam Borthakur, Guillermo Garcia-Manero, Marina Y. Konopleva, Courtney D. DiNardo, Srdan Verstovsek, Michael Andreeff, Tapan M. Kadia, Helen O. Ajufo, Rohit V. Goswamy, Carlos Blanco, Miguel Velasquez, Naval G. Daver, Naveen Pemmaraju, Sherry R. Pierce, William G. Wierda, Steven M. Kornblau, Farhad Ravandi, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1690–1699.
https://doi.org/10.1182/bloodadvances.2019001150
Published: 2020
Includes: Supplemental data
Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Clinical Trials & Observations
Curtis A. Lachowiez, Sanam Loghavi, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Kiran Naqvi, Yesid Alvarado, Musa Yilmaz, Nicholas Short, Maro Ohanian, Sherry R. Pierce, Keyur P. Patel, Wei Qiao, Jing Ning, Koji Sasaki, Koichi Takahashi, Elias Jabbour, Michael Andreeff, Farhad Ravandi, Hagop M. Kantarjian, Marina Konopleva, Courtney D. DiNardo
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1311–1320.
https://doi.org/10.1182/bloodadvances.2019001267
Published: 2020
Includes: Supplemental data
Journal Articles

LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML

Neil Beeharry, Sean Landrette, Sophia Gayle, Marylens Hernandez, Jeff E. Grotzke, Peter R. Young, Paul Beckett, Xuan Zhang, Bing Z. Carter, Michael Andreeff, Stephanie Halene, Tian Xu, Jonathan Rothberg, Henri Lichenstein
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3661–3673.
https://doi.org/10.1182/bloodadvances.2019001068
Published: 2019
Includes: Supplemental data
Journal Articles

Co-occurrence of FLT3 -TKD and NPM1 mutations defines a highly favorable prognostic AML group

Clinical Trials & Observations
Prajwal Boddu, Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Naval Daver, Sherry Pierce, Michael Andreeff, Farhad Ravandi, Jorge Cortes, Steven M. Kornblau
Journal: Blood Advances
Blood Adv (2017) 1 (19): 1546–1550.
https://doi.org/10.1182/bloodadvances.2017009019
Published: 2017
Includes: Supplemental data
Journal Articles

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Clinical Trials & Observations
Prajwal Boddu, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Srdan Verstovsek, Elias Jabbour, Gautam Borthakur, Marina Konopleva, Kapil N. Bhalla, Naval Daver, Courtney D. DiNardo, Christopher B. Benton, Koichi Takahashi, Zeev Estrov, Sherry R. Pierce, Michael Andreeff, Jorge E. Cortes, Tapan M. Kadia
Journal: Blood Advances
Blood Adv (2017) 1 (17): 1312–1323.
https://doi.org/10.1182/bloodadvances.2017008227
Published: 2017
Includes: Supplemental data